Biocon Biologics completes integration of Viatris' Biosimilar Business
The shares were up by 1.13 per cent to 241 at 11.48 am on the BSE01-12-2023
01-12-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Credit Rating
CRISIL Ratings has reaffirmed the credit ratings on bank facilities of the Company.30-11-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release titled "Biocon Biologics successfully completes integration of Viatris'' Biosimilar Business in 31 countries in Europe".30-11-2023
BIOCON LTD. - 532523 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation for loss of share certificate29-11-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Change in Directorate
Appointment of Mr. Nicholas Robert Haggar (DIN:08518863) as an Independent Director of the Company, not liable to retire by rotation, for a term commencing from September 1, 2023 till the conclusion of 48th Annual General Meeting to be held in the year 2026.29-11-2023
BIOCON LTD. - 532523 - Shareholder Meeting / Postal Ballot-Outcome of Postal Ballot
Voting Results29-11-2023
BIOCON LTD. - 532523 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Scrutinizer''s Report29-11-2023
BIOCON LTD. - 532523 - Announcement Under Regulation 30
Meeting conducted with Institutional Investors/Research Analysts27-11-2023
Biocon bets big on new class of weight-loss drugs
Company aims to ramp up portfolio as key drugsthat were actually formulated to treat diabetesgo off patent24-11-2023